Author:
Schröder C. P.,van der Graaf W. T. A.,Willemse P. H. B.,Vellenga E.,de Leij L.,Mulder N. H.,de Vries E. G. E.
Reference79 articles.
1. Rusthoven JJ, de Vries EGE, Dale DC, Piccart M, Glaspy J, Hamilton A. Consensus of the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. Int J Antimicr Agents 1997;8:263–275.
2. Scott DA, Schimpff SC. In: Klastersky J, Schimpff SC, Senn H-J (eds). Prevention of infection in cancer patients. Handbook of supportive care in Cancer New York: Marcel Dekker, Inc., 1995;45–62.
3. O’Reilly SE, Gelmon KA, Onetto N, et al. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin and fluorouracil. J Clin Oncol 1993;11:2411–2416.
4. Lamar RE, Greco FA, Johnson DH, Murphy PB, Hainsworth JD. High-dose brief duration, multiagent chemotherapy for metastatic breast cancer. Cancer 1994;73: 1842–1848.
5. Hoagland HC. Hematologic complications of cancer chemotherapy. In: Perry MC (ed). The chemotherapy source book. Baltimore: Williams and Wilkens, 1992;498–507.